Home>Topics>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals ALNY

  1. All
  2. Commentary
  3. Headlines
    1. Alnylam’s Third Quarter as Expected; Raising FVE on Pipeline Progress

      Commentary

      Thu, 6 Nov 2014

      Alnylam Pharmaceuticals reported third-quarter results that were largely consistent with our expectations and we're increasing our fair value estimate

    2. Alnylam's 2Q as Expected; Pipeline Progress Continues

      Commentary

      Fri, 8 Aug 2014

      Alnylam Pharmaceuticals reported second-quarter results that were largely consistent with our expectations, and we're maintaining our $66 fair value

    3. ALNY ’s Q1 as Expected; Strategic Deals and Pipeline Progress Underpin Improving Moat Trend

      Commentary

      Fri, 9 May 2014

      We're maintaining our $66 fair value estimate for Alnylam Pharmaceuticals after first-quarter results that were consistent with our expectations. While Alnylam continued to advance its broad RNAi pipeline

    4. I have orders in for....

      Commentary

      Sat, 8 Mar 2014

      Orders are in for the following; PRAN ARWR RLYP ALNY I have done some work looking at the newest holdings in both BIPIX and FBIOX, both great BIO TECH funds. My orders are based

    5. Maintaining Our Alnylam Fair Value as Lead Program Approaches Late-Stage Trials

      Commentary

      Fri, 8 Nov 2013

      We're maintaining our $42 fair value estimate for Alnylam Pharmaceuticals following third-quarter results that were in line with our expectations. Early in the third quarter, positive data for ALN-TTRsc

    6. Raising Our Alnylam Fair Value Estimate Based on Increased Confidence in Subcutaneous Technology

      Commentary

      Thu, 11 Jul 2013

      We're raising our fair value estimate for Alnylam ALNY to $42 per share from $31, as positive data for ALN-TTRsc came close on the heels of positive data for ALN-TTR02 earlier

    7. Alnylam's hereditary disease treatment shows promise, shares soar

      Headlines

      Mon, 16 Jul 2012

      (Reuters) - Alnylam Pharmaceuticals Inc's stock soared more than 50 percent after the company reported that its experimental drug to treat an organ-damaging hereditary disorder showed promise in an...

    8. Alnylam Validates Technological Progress With TTR02, Highlighting Its Most Promising Pipeline Drug

      Commentary

      Mon, 16 Jul 2012

      We're raising our fair value estimate following Alnylam's ALNY announcement of strong Phase I data from ALN-TTR02, an RNA interference therapy for a rare disease known as TTR amyloidosis

    9. Alnylam Sees Progress in Biotherapeutics, but No Impact to Our Fair Value Estimate

      Commentary

      Tue, 22 Feb 2011

      We're maintaining our fair value estimate for shares of Alnylam ALNY after the company reported 2010 results that were in line with our estimates. Alnylam announced that it was able to form two recent

    10. Alnylam Under Review After Loss of Key Collaboration

      Commentary

      Wed, 17 Nov 2010

      We're putting Alnylam Pharmaceuticals ALNY under review after partner Roche RHHBY announced plans to terminate its work in siRNA as part of a cost-cutting and restructuring

    « Prev123Next »
    Content Partners